• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.抗Xa监测可提高严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者低分子量肝素的疗效。
Thromb Res. 2020 Dec;196:432-434. doi: 10.1016/j.thromres.2020.09.039. Epub 2020 Oct 8.
2
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.磺达肝癸钠在非危重症COVID-19患者中的危害：与依诺肝素的回顾性对照研究
Thromb Res. 2020 Dec;196:395-397. doi: 10.1016/j.thromres.2020.09.024. Epub 2020 Sep 17.
3
Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.依诺肝素用于伴有 2019 冠状病毒病的门诊患者的一级血栓预防（OVID 研究）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 9;21(1):770. doi: 10.1186/s13063-020-04678-4.
4
Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin.循环肝素硫酸链和体重会影响使用预防性依诺肝素剂量的癌症患者的抗 Xa 水平。
J Thromb Thrombolysis. 2020 Jul;50(1):112-122. doi: 10.1007/s11239-020-02128-1.
5
Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.部分凝血活酶时间在肝素化儿科心脏手术后患者的出血预测中比抗 Xa 水平更有意义。
J Thorac Cardiovasc Surg. 2018 Jul;156(1):332-340.e1. doi: 10.1016/j.jtcvs.2018.02.101. Epub 2018 Apr 4.
6
Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.低分子肝素在实体器官移植受者中的剂量调整和监测。
Clin Transplant. 2013 Nov-Dec;27(6):852-7. doi: 10.1111/ctr.12240. Epub 2013 Sep 6.
7
Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.重症监护病房中感染 SARS-CoV2 的患者的肝素剂量、水平和耐药性。
Int J Lab Hematol. 2021 Dec;43(6):1284-1290. doi: 10.1111/ijlh.13543. Epub 2021 Apr 14.
8
Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.评估依诺肝素剂量作为肺移植受者出血危险因素的情况。
Ann Pharmacother. 2016 Oct;50(10):824-31. doi: 10.1177/1060028016656434. Epub 2016 Jun 29.
9
Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.接受依诺肝素抗凝治疗的医疗患者的非治疗性抗 Xa 水平。
Thromb Res. 2013 Oct;132(4):433-6. doi: 10.1016/j.thromres.2013.08.017. Epub 2013 Aug 30.
10
Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: A randomized cross-over trial.低分子量肝素依诺肝素经动脉管路与静脉管路给药用于预防血液透析或血液滤过患者体外血液循环中血栓形成的随机交叉试验
Nephrology (Carlton). 2016 Aug;21(8):663-8. doi: 10.1111/nep.12681.

引用本文的文献

1
Thromboelastography in COVID-19 patients: An observational study in the South African context.COVID-19患者的血栓弹力图：南非背景下的一项观察性研究。
Afr J Lab Med. 2025 Jun 26;14(1):2681. doi: 10.4102/ajlm.v14i1.2681. eCollection 2025.
2
Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism.重症静脉血栓栓塞患者依诺肝素的最佳剂量
Innov Pharm. 2023 Oct 10;14(1). doi: 10.24926/iip.v14i1.5174. eCollection 2023.
3
[Clinical experience in prophylactic enoxaparin dosage adjustment guided by anti-Xa factor levels in critical care patients with COVID-19 pneumonia: Observational study].[以抗Xa因子水平为指导调整COVID-19肺炎重症患者预防性依诺肝素剂量的临床经验：观察性研究]
Med Intensiva. 2023 May 8. doi: 10.1016/j.medin.2023.04.012.
4
Impact of COVID-19 on Nonpulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes.新型冠状病毒肺炎对非肺部危重症的影响：患病率、临床表现、治疗及预后。
Clin Chest Med. 2023 Jun;44(2):249-262. doi: 10.1016/j.ccm.2022.11.011. Epub 2022 Nov 23.
5
Perioperative Complications of Patients with SARS-CoV-2 Infection in Neurosurgery.神经外科中感染新型冠状病毒2的患者围手术期并发症
J Clin Med. 2022 Jan 27;11(3):657. doi: 10.3390/jcm11030657.
6
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.新型冠状病毒肺炎血栓形成风险的当前和新型生物标志物：国际新型冠状病毒肺炎血栓形成生物标志物座谈会共识声明。
Nat Rev Cardiol. 2022 Jul;19(7):475-495. doi: 10.1038/s41569-021-00665-7. Epub 2022 Jan 13.
7
Complications of Critical COVID-19: Diagnostic and Therapeutic Considerations for the Mechanically Ventilated Patient.危重症 COVID-19 的并发症：机械通气患者的诊断和治疗注意事项。
Chest. 2022 Apr;161(4):989-998. doi: 10.1016/j.chest.2021.10.011. Epub 2021 Oct 13.
8
Nuts and bolts of COVID-19 associated coagulopathy: the essentials for management and treatment.新型冠状病毒病相关凝血障碍的要点：管理和治疗的要点。
Postgrad Med. 2021 Nov;133(8):899-911. doi: 10.1080/00325481.2021.1974212. Epub 2021 Sep 11.
9
Thromboprophylaxis in COVID-19 - Rationale and considerations.COVID-19 相关的血栓预防——基本原理和注意事项。
Adv Biol Regul. 2021 Aug;81:100819. doi: 10.1016/j.jbior.2021.100819. Epub 2021 Jul 23.
10
Thromboprophylaxis strategies to improve the prognosis of COVID-19.改善新型冠状病毒肺炎预后的血栓预防策略。
Vascul Pharmacol. 2021 Aug;139:106883. doi: 10.1016/j.vph.2021.106883. Epub 2021 Jun 4.

本文引用的文献

1
Thromboprophylaxis in COVID-19: Anti-FXa-the Missing Factor?2019冠状病毒病的血栓预防：抗Xa因子——缺失的因素？
Am J Respir Crit Care Med. 2020 Aug 1;202(3):455-457. doi: 10.1164/rccm.202005-1654LE.
2
Heparin resistance in COVID-19 patients in the intensive care unit.COVID-19 患者在重症监护病房中肝素耐药。
J Thromb Thrombolysis. 2020 Aug;50(2):287-291. doi: 10.1007/s11239-020-02145-0.
3
Coagulation abnormalities and thrombosis in patients with COVID-19.新型冠状病毒肺炎患者的凝血异常与血栓形成
Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.
4
Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.确认 COVID-19 重症 ICU 患者的血栓并发症累积发生率较高：更新分析。
Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30.
5
Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2.感染新型冠状病毒（SARS-CoV-2）患者的血栓栓塞事件及明显的肝素抵抗
Int J Lab Hematol. 2020 Jun;42 Suppl 1(Suppl 1):19-20. doi: 10.1111/ijlh.13230.
6
Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.肝素抗凝剂治疗静脉血栓栓塞症的实际管理指南。
J Thromb Thrombolysis. 2016 Jan;41(1):165-86. doi: 10.1007/s11239-015-1315-2.
7
The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis.低分子量肝素血栓预防的抗Xa因子范围
Hematol Rep. 2015 Nov 23;7(4):5844. doi: 10.4081/hr.2015.5844.
8
Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.肾功能损害和肥胖患者中的低分子量肝素：医疗和外科环境中的现有证据及临床实践建议
Ann Pharmacother. 2009 Jun;43(6):1064-83. doi: 10.1345/aph.1L194. Epub 2009 May 19.
9
Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin.
Blood. 1991 Nov 1;78(9):2337-43.

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.

作者信息

Trunfio Mattia, Salvador Elena, Cabodi Daniela, Marinaro Letizia, Alcantarini Chiara, Gaviraghi Alberto, Trentalange Alice, Lipani Filippo, Sciascia Savino, Roccatello Dario, Bonora Stefano, Di Perri Giovanni, Calcagno Andrea

机构信息

Department of Medical Sciences, University of Torino at Infectious Diseases Unit, Amedeo di Savoia Hospital, Torino, Italy.

Department of Medical Sciences, University of Torino at Infectious Diseases Unit, Amedeo di Savoia Hospital, Torino, Italy.

出版信息

Thromb Res. 2020 Dec;196:432-434. doi: 10.1016/j.thromres.2020.09.039. Epub 2020 Oct 8.

DOI:10.1016/j.thromres.2020.09.039
PMID:33049598
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7543686/
Abstract
摘要